Metastatic Synovial Sarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Metastatic Synovial Sarcoma Market Outlook

Thelansis’s “Metastatic Synovial Sarcoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Metastatic Synovial Sarcoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Metastatic Synovial Sarcoma Overview

Synovial sarcoma accounts for approximately 8%–10% of all soft tissue sarcomas (STS). This malignancy can be diagnosed at any age but predominantly occurs in young adults, particularly those aged 15 to 35 years, with a higher incidence in males. Despite its relative rarity, synovial sarcoma is the third most common STS affecting the extremities. The median age at diagnosis is 35 years. The term "synovial sarcoma" is a misnomer, as the tumor does not originate from synovial tissue. It may arise near joints but never within them, and its precise cellular origin remains undefined. Additionally, synovial sarcoma can be found in regions without an apparent relationship to synovial structures, including the head and neck (<10%), thoracic and abdominal wall (<10%), and intrathoracic sites. Synovial sarcoma is an aggressive form of STS with a significant propensity for recurrence and metastasis. Approximately 50% of patients develop metastatic disease, either at initial presentation or during the disease course. The lungs are the most common site of metastasis (74%–81%), followed by lymph nodes (3%–23%) and bones (10%–20%). Surgical resection is the standard treatment for synovial sarcoma, aiming to remove the tumor along with a margin of surrounding tissue to ensure complete excision. Depending on the extent of cancer spread, this may necessitate the removal of an entire muscle or muscle group.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: